title: [Long-term results of chemoembolization for hepatocarcinoma].
abstract: We reviewed the long-term results of transcatheter arterial chemoembolization in the treatment of inoperable hepatocellular carcinoma (HCC) complicating cirrhosis; the survival analysis was used to assess the clinical efficacy of the procedure. Several chemoembolization protocols are discussed because no standard treatment exists. Literature data show cumulative survival rates after chemoembolization for an HCC to range 60% to 80% at one year and 40% to 50% at two years; comparative studies, although contradictory, show a trend of chemoembolization to prolong survival in patients with inoperable carcinoma. The main prognostic factors are tumor size and extent, liver function impairment, the grade of Lipiodol tumor uptake, and the tumor response to therapy. The complication rates of chemoembolization vary largely in the literature, mainly because of the different standards used to define adverse events. Chemoembolization morbility rate is usually high, ranging 20% to 55%, but most complications are generally well treated with conservative management. The mortality rate is usually very low and well acceptable for a palliative anticancer therapy. In conclusion, chemoembolization is clinically effective in prolonging survival in cirrhotic patients with HCC; the lack of any reliable alternative therapy makes chemoembolization play a major role in the treatment of HCC when surgery or percutaneous ethanol injection are unfeasible.
authors.affiliation: Istituto di Radiologia, Università degli Studi, Padova.
authors.forename: G P
authors.initials: GP
authors.lastname: Feltrin
authors.forename: S
authors.initials: S
authors.lastname: Savastano
authors.forename: A
authors.initials: A
authors.lastname: Marangon
authors.forename: D
authors.initials: D
authors.lastname: Miotto
authors.forename: M
authors.initials: M
authors.lastname: Chiesura-Corona
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D015996:Survival Rate; D013997:Time Factors